Bristol-Myers Squibb Co.: PharmaVitae Profile

• Publication date: March 2011

Introduction This analysis examines the historical and forecast performance for Bristol-Myers Squibb in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. Features and benefits * Gain insight into Bristol-Myers Squibb's strategic outlook across the next 6 yea...

Introduction

This analysis examines the historical and forecast performance for Bristol-Myers Squibb in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.

Features and benefits

* Gain insight into Bristol-Myers Squibb's strategic outlook across the next 6 years
* Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source

Highlights

Strategic insight into the prospects for BMS over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.

Your key questions answered

* Benchmark BMS's performance against key rivals in the prescription pharmaceutical sector
* Determine the value of BMS's piepline and other strategies the company is taking to counteract an imminent wave of generic compeitition.
* Assess what makes BMS a model biopharma company and why its newfound focus could lead to the industry's next megamerger.

Pathology Industry in Japan

Executive Summary
Insomnia prevalence driven by aging populations
OVERVIEW
Catalyst
Summary
DISEASE DEFINITION AND DIAGNOSIS CRITERIA
Definition of insomnia
Diagnostic criteria
GLOBAL VARIATION AND HISTORICAL TRENDS
Evolving insomnia definition resulted in variable prevalence rates
Prevalence: secondary prevalence caused by mental disorders is most common
Incidence: acute insomnia of short duration is not clinically considered
CO-MORBIDITIES
Insomniacs often suffer from psychiatric disorders, medical conditions, and physical pain
RISK FACTORS
Age and gender
Age: insomnia prevalence increases with advancing age
Gender: insomnia is more prevalent in females than males
Mental and physical conditions
Mental health conditions pose the greatest risk factor for insomnia
Physical condition: pain is the most common physical cause of insomnia
Medical conditions: bidirectional causality
EPIDEMIOLOGIC FORECASTING OF INSOMNIA
Sources of epidemiologic data
Description of methods
US
Japan
France
Germany
Italy
Spain
UK
EPIDEMIOLOGIC RESULTS
Estimated prevalent cases of insomnia and future trends
Segmentation of prevalent cases
DISCUSSION
Strengths and limitations
BIBLIOGRAPHY
Journal papers
Websites
APPENDIX
Report methodology